Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis positive over new drug

Novartis positive over new drug

10th April 2008

Novartis’ new drug in development, ACZ885, shows potential for treating serious life-long autoinflammatory diseases, the firm has claimed.

Following trials of the drug, it was discovered that patients with inherited autoinflammatory diseases achieved long-lasting remission after treatment.

The firm notes that a number of symptoms, including fever, skin rashes and joint pain can be caused by autoinflammatory diseases and that they can lead to severe complications.

Trevor Mundel, head of global development functions at Novartis Pharma AG said: “The latest findings are a promising step forward for patients with rare autoinflammatory diseases.”

He added that the firm was optimistic that ACZ885 could become an “innovative treatment” for patients with certain types of inflammatory diseases.

Results of the phase II study suggest that ACZ885 could prove to be a new advance in the treatment of cryopyrin-associated periodic syndromes, as patients treated with the drug showed an improvement within one day and remission within seven days.

Novartis earlier this week announced it was to acquire a 25 per cent stake in Alcon from Nestle.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.